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Abstract 
We have recently demonstrated the safety and tolerability of a novel therapeutic 
regimen employing autologous blood cells chemically coupled with seven myelin 
peptides to induce antigen-specific tolerance in MS (ETIMS study). The aim of the 
current study was an extended safety analysis to assess the effect of the ETIMS 
approach on antibodies to common autoantigens, the myelin peptides used and 
common recall antigens. None of the patients showed induction of autoantibody 
responses. One patient had a measurable myelin peptide-specific response at 
baseline, which was reduced after treatment. Total immunoglobulins and recall 
antibody responses showed no significant change. 
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Introduction 
MS is the most common disabling neurological disease in young adults. It is widely 
accepted that damages in the CNS results from a CD4+-mediated autoimmune attack 
against myelin sheath associated antigens. 1 We previously established an antigen-
specific tolerance protocol that selectively targets these auto-reactive T-cells, 
employing autologous peripheral blood mononuclear cells (PBMC) pulsed with  
seven myelin peptides of myelin oligodendrocyte glycoprotein (MOG1-20, MOG35-
55), myelin basic protein (MBP13-32, MBP83-99, MBP111-129, MBP146-170) and 
proteolipid protein (PLP139-154) and chemically fixed with the cross linker EDC. We 
demonstrated the feasibility, safety and tolerability of a single infusion of chemically 
peptide-coupled PBMCs as tolerogenic vaccine in an open label, single center, dose 
escalation phase I trial (ETIMS trial). 2 Furthermore, patients receiving more than 
1x109 peptide-coupled cells showed a decrease in antigen-specific T cell responses.  
The aim of this study was to expand our safety analysis on ETIMS-treated patients 
analyzing the effect of antigen-coupled cells on the antibody responses against the 
target myelin peptides, common autoantigens, and recall antigens. 
 
Patients and Methods 
Patients and serum samples 
The ETIMS trial was performed with approval of the ethics board of physicians of the 
University Hospital Hamburg-Eppendorf. 2 In the dose escalation study, patients 
received a single infusion of autologous antigen-coupled cells at day 0 (individual 
doses shown in Table 1). Serum samples were taken from MS patients, one month 
before, three (patients #1-#7 and #9) or six (patient #8) months and 12 months (all 
patients) after treatment. All serum samples were stored at -80°C. Furthermore, all 
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patients had a measurable T cell response to at least one of the peptides used in the 
trial, at baseline. 2 
 
Antibody assays 
All serum samples were analyzed for IgG antibodies to native human MOG by a live 
cell based immunoassay (CBA) as described before. 3 Screening was done at 1:20 
and 1:40 dilutions and samples were scored positive at a titer >1:160. 
Serum (1:100 diluted) IgG antibodies against the seven different peptides MOG1-20, 
MOG35-55, MBP13-32, MBP83-99, MBP111-129, MBP146-170 and PLP139-154 
used in the ETIMS trial and against human MBP were analyzed by enzyme-linked 
immunosorbent assay (ELISA) as described before. 4, 5 A cut-off value of 0.5 optical 
density units was chosen to indicate positive antibody responses.  
For the determination of rheumatoid factors (RF) and IgG antibodies against tetanus 
toxin, rubella, measles, anti-citrullinated peptide (CCP) and phospholipids 
commercially available ELISA kits from IBL International (Hamburg, Germany) were 
used. IgG antibodies to EBNA-1 and CMV were analyzed using ELISA kits from 
Euroimmun (Luebeck, Germany). Anti-nuclear antibody (ANA) were analyzed by 
indirect immunofluorescence (IIF) in HEp-20-10 cells using an IIF kit from Euroimmun.  
Serum samples were analyzed for total IgG, IgM and IgA levels using a Beckman 
clinical nephelometer (Beckman Coulter).  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad, USA).  
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Results 
In this study we aimed to investigate antibody responses against myelin peptides, 
native human MOG, common autoantigens and recall antigens in patients treated 
with the ETIMS approach (Figure and Table 2). None of the patients had antibodies 
against native MOG, CCP, phospholipids and RF, whereas two patients had ANAs 
(patients #2 and #7) and two patients had anti-MBP antibodies (patients #5 and #7). 
In patient #5 anti-MBP antibody levels were reduced (>2-fold change) three and 
twelve months after treatment (Figure). Importantly, no new autoantibody responses 
were induced by the treatment (Figure and Table 2).  
Only one patient (patient #2) had measurable antibody reactivities against 8 of 9 
myelin peptides used in the trial. These antibody responses were reduced (>2-fold 
change) three and twelve months after treatment (Figure). However, this reduction 
was also seen for RF levels (>2-fold change). 
Finally antibody responses to common recall antigens and total serum albumin and 
Ig levels were tested to address a peptide-specific effect of this therapy and to 
potentially exclude unspecific responses to the treatment. Overall antibody 
responses and Ig levels were not altered (>2-fold change) by the treatment (Figure, 
Table 2).  
 
Discussion 
In this extension study we analyzed the influence of the ETIMS approach on the 
antibody reactivity to common autoantigens, the myelin peptides used and common 
recall antigens. An important safety issue of antigen-specific tolerization is the 
induction of immune responses against the tolerizing antigen or even new 
autoantigens. Therefore, we were interested to asses changes in antibody responses 
to myelin peptides used for tolerization, native human MOG and MBP, other targets 
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of autoimmunity responses and recall and control antibodies in any of the treated 
patients. As one important result of the safety analysis, we did not observe an 
increase in anti-myelin antibody reactivity, supporting the safety of the approach with 
regard to a potential induction of autoimmune responses as observed in previous 
tolerization strategies. 6 Next we were interested to exclude potential induction of 
new autoimmunity by the treatment. Since antigen-coupled cells are known to 
undergo apoptosis after treatment 2, 7, there is a concern about induction of ANAs. In 
several autoimmune diseases, including lupus, mixed connective tissue disease and 
others, antibodies against nuclear antigens (e.g. ANA) are thought to be stimulated 
and sustained by apoptotic cells. In the current study we could not observe induction 
of ANAs in any of the patients. Likewise, we did not detect an induction of anti-CCP, 
anti-phospholipid antibodies or RF in any of the patients.  
We found a positive antibody response to 8/9 myelin peptides in one single patient 
(#2) at baseline. Since this patient was negative for antibodies to native MOG it is 
very unlikely that these peptide-specific antibodies have a pathogenic role, although 
they still might reflect tissue damage and ongoing neuorinflammation. 3, 8-10 There 
was a clear reduction in myelin peptide specific antibody responses following ETIMS 
treatment. However, we have also observed a reduction of RF and anti-rubella 
antibodies thus challenging the specificity of the effect. 
In summary the extended safety analysis of the ETIMS phase I study does not 
suggest an increase in autoantibodies or induction of new autoantibody reactivities in 
MS patients treated with the ETIMS approach. The results underscore the safety of 
this novel antigen-specific therapy.  
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Figure: Effect of ETIMS treatment on antibody levels to common autoantigens, the 
petides used for tolerance induction and common recall antigens. Antibody 
responses to myelin peptides and MBP were measured by ELISA, whereas 
antibodies to native human MOG were measured by CBA. Serum antibodies to recall 
antigens (tetanus, measles and rubella), common viruses (EBV and CMV), ANA, 
CCP, RF and phospholipids were measured by ELISA and ANA were measured by 
indirect immunofluorescence. Graphs show the individual antibody levels before 
therapy and 3/6 and 12 months after ETIMS treatment. Cut-off values are indicated 
by the dashed lines. Values are shown as antibody titers, antibody concentration in 
IU/ml, OD units or mg/dl.  !
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Table 1. Clinical data and treatment regimens of patients. 
Patients Cell dose1 Age Sex MS Duration2 EDSS 
# 1 1x103 49 f SP 5 3.5 
# 2 1x105 39 f RR 5 1.5 
# 3 1x107 27 f RR 2 1 
# 4 1x108 42 f RR 2 1.5 
# 5 5x108 44 f RR 16 4 
# 6 1x109 43 f SP 13 4.5 
# 7 1x109 34 f RR 2 1.5 
# 8 2.5x109 42 f RR 4 1.5 
# 9 3x109 42 m RR 3 2 
1) Cell dose is given as the number of antigen-coupled cells infused; 2) duration of disease in years. f: female; m: male; MS: multiple sclerosis; SP: secondary-progressive; RR: 
relapsing-remitting; EDSS: expanded disability status scale !! !
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Table 2. Antibody and serum protein levels after ETIMS treatments. 
Antigen -1 month +3/6 months +12 months P-value 
Autoantibodies 
MOG-IgG CBA 0 (0%) 0 (0%) 0 (0%) 1.000 1 
MBP-IgG 2 (22%) 1 (11%) 1 (11%) 0.746 1 
ANA-IgG 2 (22%) 2 (22%) 2 (22%) 1.000 1 
CCP-IgG 0 (0%) 0 (0%) 0 (0%) 1.000 1 
Rheumatoid factor 0 (0%) 0 (0%) 0 (0%) 1.000 1 
Phospholipid-IgG 0 (0%) 0 (0%) 0 (0%) 1.000 1 
Anti-peptide antibodies 
MOG(1-20)-IgG 1 (11%) 0 (0%) 0 (0%) 0.354 1 
MOG(35-55)-IgG 1 (11%) 0 (0%) 0 (0%) 0.354 1 
MBP(13-32)-IgG 1 (11%) 0 (0%) 0 (0%) 0.354 1 
MBP(83-99)-IgG 1 (11%) 0 (0%) 0 (0%) 0.354 1 
MBP(111-129)-IgG 1 (11%) 0 (0%) 0 (0%) 0.354 1 
MBP(146-170)-IgG 0 (0%) 0 (0%) 0 (0%) 1.000 1 
! 13!
PLP(139-153)-IgG 1 (11%) 0 (0%) 0 (0%) 0.354 1 
Anti-viral and vaccine antibodies (common recall antigens) 
Measles-IgG  9 (100%) 9 (100%) 9 (100%) 1.000 1 
Rubella-IgG  8 (89%) 9 (100%) 9 (100%) 0.354 1 
Tetanus-IgG  9 (100%) 9 (100%) 9 (100%) 1.000 1 
EBNA1-IgG  9 (100%) 9 (100%) 9 (100%) 1.000 1 
CMV-IgG  2 (22%) 2 (22%) 2 (22%) 1.000 1 
Serum proteins 
Albumin (mg/dl) 3  4277 (263)  4374 (204)  4233 (211 ) 0.313 2 
Total-IgG (mg/dl) 3  1059 (256)  1061 (223)  1055 (235 ) 0.362 2 
Total-IgM (mg/dl) 3  148 (49)  149 (223)  149 (53) 0.971 2 
Total-IgA (mg/dl) 3  273 (173)  266 (161)  270 (177) 0.701 2 
 
1 significance of group differences analyzed by Chi-Square test or 2 repeated-measures one-way ANOVA, 3 data are shown as mean 
(standard deviation). !!
